. Moderna and Pfizer-BioNTech vaccines prime T cells to fight SARS-CoV-2 variants, study finds « JO LEE MAGAZINE

SCIENCE DAILY – Researchers at La Jolla Institute for Immunology (LJI) have found that T cells from people who have recovered from COVID-19 or received the Moderna or Pfizer-BioNTech vaccines are still able to recognize several concerning SARS-CoV-2 variants. Their new study, published online on July 1, 2021 in Cell Reports Medicine, shows that both CD4+ “helper” T cells and CD8+ “killer” T cells can still recognize mutated forms of the virus. This reactivity is key to the body’s complex immune response to the virus, which allows the body to kill infected cells and stop severe infections. “This study suggests that the impact of mutations found in the variants of concern is limited.”

Continue Reading at SCIENCE DAILY

World on the Run | Jo Lee Magazine




Comments are closed.

 

 


hey